BioMarin Pharmaceutical Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioMarin Pharmaceutical Inc.
From the latest COVID-19 advances to the emergence of game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.
Colorado-based Bolder recently announced the global launch of the CoolSeal vessel sealing platform, which will complement Hologic’s obstetrical/gynecological surgery product line.
Among other Asia deals, Takeda adds to pair of recent gene therapy tie-ups with a CNS-focused cell therapy partnership with Immusoft; earlier it licensed ex-US rights to JCR’s Hunter syndrome drug.
Experts in drug development, clinical care and digital therapeutics discuss gaps in the treatment landscape for Alzheimer’s disease, as well as opportunities for prevention and innovation in care delivery.
- Other Names / Subsidiaries
- Huxley Pharmaceuticals, Inc.
- LEAD Therapeutics, Inc.
- Prosensa Holding N.V
- Zacharon Pharmaceuticals, Inc.
- ZyStor Therapeutics, Inc.